U.S. Mortgage REITs Stock News

The latest round of Section 301 and Section 338 tariffs is prompting investors to reconsider how exposed portfolios are to complex global supply chains. Higher duties, extra compliance checks and uncertain trade rules can all squeeze margins or re-route production closer to home. That is where a curated US manufacturing and onshoring screener can help focus attention. It filters for larger, financially healthy companies with operations rooted in North America. In this article, you will see...

TechnipFMC (FTI) is back in focus after reporting higher second quarter and first half 2026 revenue and net income compared with last year, while also reaffirming full year revenue guidance for its Subsea and Surface Technologies segments. See our latest analysis for TechnipFMC. TechnipFMC’s results and reaffirmed guidance come after a strong run, with the share price delivering a 51.47% year to date share price return and a very large 5 year total shareholder return. This is despite the 7...

TriMas Corporation’s recent second-quarter and six-month 2026 results showed slightly higher sales of US$174.58 million and US$342.86 million respectively, alongside lower quarterly net income of US$13.37 million but a very large six‑month net income of US$814.2 million, while continuing its share repurchase program and affirming a US$0.0400 quarterly dividend. Beneath the headline numbers, the combination of improved profitability from continuing operations, a long-running buyback that has...

Sonic Automotive, Inc. reported past second-quarter 2026 results with revenue of US$3,934.0 million and net income of US$57.4 million, completing another US$6.82 million share buyback tranche and affirming a US$0.41 per-share dividend. The swing from a prior-year quarterly net loss to profit, alongside long-running buybacks totaling about US$1.29 billion, highlights management’s ongoing emphasis on shareholder returns and operational improvement. We’ll now examine how this return to...

Excelerate Energy (EE) is back in focus after its board approved a quarterly cash dividend of $0.09 per Class A share for the June 2026 quarter, representing a 13% increase from the prior payout. See our latest analysis for Excelerate Energy. Excelerate Energy’s recent dividend decision comes after a strong run in the stock, with a 90-day share price return of about 13.9% and a year to date share price return of 38.6%. The 1 year total shareholder return sits above 55%, signaling firm...

Jackson Financial (JXN) is entering a planned leadership transition that will place longtime finance executive Don W. Cummings in the Chief Executive Officer role and elevate Brian M. Walta to Chief Financial Officer. See our latest analysis for Jackson Financial. Jackson Financial’s leadership reshuffle arrives during a period of strong stock momentum, with a 30 day share price return of 16.98%, year to date share price return of 13.79%, and a 1 year total shareholder return of 50.40%,...

Callaway Golf Company recently reported its Q2 results after market hours, following a prior quarter in which it exceeded analysts’ revenue expectations and issued guidance that was stronger than anticipated. This time around, investors are focused on whether Callaway can deliver on expectations for year-on-year revenue to hold steady after last year’s decline, which could signal stabilizing demand across its golf entertainment and equipment businesses. Now we’ll examine how improving...

Iovance Biotherapeutics recently drew heightened attention as it prepared to report its second quarter 2026 results and corporate updates, including early commentary on the commercial rollout of its FDA-approved T cell therapy for solid tumors, Amtagvi. This focus on Amtagvi’s initial uptake and the company’s funding and execution risks has sharpened the debate over how fully Iovance’s long-term potential is reflected in its current valuation. We’ll now examine how the upcoming Amtagvi...

Teleflex Incorporated recently received U.S. FDA Biologics License Application approval for EZPLAZ Freeze Dried Plasma, the first FDA-licensed freeze dried plasma for adult transfusions when conventional plasma products are unavailable. This approval gives Teleflex its first biologics license for a blood component and introduces a patented flexible bag format that addresses battlefield and prehospital trauma care logistics. We’ll now examine how this first-of-its-kind FDA-approved freeze...

Silicon Laboratories stock snapshot after recent performance Silicon Laboratories (SLAB) recently closed at $217.50, with the stock roughly flat over the past week and month. Returns over the past 3 months also appear broadly steady, while longer term performance remains stronger. See our latest analysis for Silicon Laboratories. Silicon Laboratories shows strong longer term momentum, with a year to date share price return of 64.9% and a 1 year total shareholder return of 62.9%, even as very...

BorgWarner (BWA) stock is drawing attention after new program awards for its eTurbo hybrid system and torque on demand transfer case signaled fresh business in advanced hybrid and SUV drivetrains. See our latest analysis for BorgWarner. Alongside the new hybrid and SUV program wins, BorgWarner’s share price has climbed with a 12.28% 90 day share price return and 36.66% year to date share price return, while the 1 year total shareholder return of 72.15% points to strong momentum that has built...

The St. Joe Company recently reported past second-quarter 2026 results, with revenue of US$158.83 million and net income of US$40.47 million, and its board declared a US$0.16 per-share cash dividend payable in September 2026. Together with ongoing share repurchases that have retired a very large portion of its stock since 1998, these results underline management’s continued focus on shareholder returns. We’ll now examine how this combination of earnings growth and a reaffirmed cash dividend...

Arcus Biosciences (RCUS) drew fresh investor attention after announcing a clinical collaboration with Summit Therapeutics to test casdatifan plus ivonescimab in metastatic clear cell renal cell carcinoma within its ARC-20 platform. See our latest analysis for Arcus Biosciences. Arcus Biosciences shares trade at US$28.19, with the stock delivering a 21.04% year to date share price return and a very large 207.75% total shareholder return over the past year, suggesting recent news and clinical...

Capitol Federal Financial, Inc. recently reported third-quarter 2026 results, including US$53.48 million in net interest income, US$23.57 million in net income, minimal net charge-offs of US$148,000, completion of a 9,976,478-share buyback totaling US$72.84 million, and reaffirmed a US$0.085 quarterly dividend per share. Together, higher net interest income, growing net income and the completed share repurchase program underscore management’s clear emphasis on capital return and operating...

MetroCity Bankshares earnings trigger fresh interest MetroCity Bankshares (MCBS) has drawn investor attention after reporting second quarter 2026 results, with net interest income of $44.04 million and net income of $22.13 million, both higher than the prior year period. See our latest analysis for MetroCity Bankshares. MetroCity Bankshares has seen mixed trading around the earnings release, with the share price slipping 4.09% over the past month but still posting a 34.68% year to date share...

Leonardo DRS, Inc. recently reported past second-quarter 2026 results showing sales of US$913 million and net income of US$86 million, reaffirmed its full-year 2026 revenue guidance, declared a US$0.09 per-share dividend, updated progress on its share repurchase program, and agreed to acquire AI mission software firm Raft LLC for US$450 million in cash. Beyond the headline growth in revenues and earnings, the planned Raft acquisition and raised profitability guidance highlight Leonardo DRS’s...

Why First Busey’s latest earnings and buyback matter for investors First Busey (BUSE) has drawn fresh attention after second quarter and year to date results showed much higher net income and earnings per share, alongside the completion of a multi year share repurchase program. See our latest analysis for First Busey. At a share price of $30.86, First Busey has delivered a 15.97% 90 day share price return and a 45.10% 1 year total shareholder return, which indicates that recent earnings and...

Eton Pharmaceuticals (ETON) has filed a Prior Approval Supplement with the U.S. Food and Drug Administration to expand KHINDIVI’s label to younger pediatric patients, following bioequivalence data versus ALKINDI SPRINKLE hydrocortisone granules. See our latest analysis for Eton Pharmaceuticals. The KHINDIVI label expansion filing comes after a very strong run in Eton Pharmaceuticals’ stock, with a 30 day share price return of 26.73%, a 90 day share price return of 60.62% and a year to date...

In late July 2026, Myriad Genetics reported second-quarter results showing revenue of US$190.7 million versus US$213.1 million a year earlier, alongside a reduced full-year 2026 revenue outlook of US$770 million to US$790 million due to weaker Prenatal Health test volumes and more cautious assumptions for revenue per test. Despite the revenue decline, the company’s net loss narrowed sharply to US$43.2 million from a very large loss a year ago, highlighting significant cost or non-operational...

In July 2026, Customers Bancorp, Inc. reported second-quarter 2026 results showing net interest income of US$193.37 million and net income of US$71.56 million, alongside slightly higher net charge-offs of US$14.58 million and continued execution of its share repurchase program. The company highlighted efficiency gains from its proprietary AI-powered workflow automation and faster commercial loan processing as key contributors to its earnings performance and operational improvement. Next,...

Q2 results and capital return actions in focus for Hyatt Hotels stock Hyatt Hotels (H) has drawn investor attention after its second quarter 2026 earnings, the Board-approved third quarter dividend, an updated full-year net income outlook, and progress on a multi-year share repurchase program. See our latest analysis for Hyatt Hotels. Despite Q2 earnings, guidance and capital returns in focus, Hyatt Hotels shares have pulled back recently, with the 30 day share price return down 8.8% and the...

In late July 2026, Core Scientific, Inc. reported Q2 2026 revenue of US$164.2 million alongside a net loss of US$1.16 billion, and announced a large‑scale AI infrastructure partnership with Advanced Micro Devices, Inc. involving up to 2.5 gigawatts of potential data center capacity and related stock warrants for Advanced Micro Devices, Inc. Core Scientific, Inc. also added veteran technology executive Mark W. Adams to its expanded seven‑member Board of Directors, strengthening oversight as...

Tariffs on Canadian imports and higher taxes on generic drugs are shaking up expectations for costs and pricing across healthcare. For U.S. specialty pharmaceutical manufacturers, this mix of pressure and opportunity can be important. Some companies may face higher input costs. Others with more domestic production may see a relative edge if imported generics become more expensive. This article explains how the new trade measures could matter for your portfolio and discusses 3 U.S. specialty...

Last week saw the newest quarterly earnings release from BigBear.ai Holdings, Inc. ( NYSE:BBAI ), an important...